JAC Advance Access originally published online on July 19, 2006
Journal of Antimicrobial Chemotherapy 2006 58(3):701-704; doi:10.1093/jac/dkl298
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis
1 Division of Pulmonary & Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center 388-1 Pungnap-dong, Songpa-gu, Seoul, Korea 2 Department of Diagnostic Laboratory Medicine, University of Ulsan College of Medicine, Asan Medical Center Seoul, Korea
Received 15 March 2006; returned 31 May 2006; revised 23 June 2006; accepted 2 July 2006
*Corresponding author. Tel: +82-2-3010-3892; Fax: +82-2-3010-6968; E-mail: shimts{at}amc.seoul.kr
Objectives: Although linezolid has good in vitro activity against Mycobacterium tuberculosis, its long-term use in the treatment of multidrug-resistant tuberculosis (MDR-TB) may be limited by its cost and serious adverse reactions. We therefore evaluated the efficacy and tolerability of a reduced dose of linezolid, in combination with other anti-TB drugs, in patients with intractable or extensive MDR-TB.
Methods: MDR-TB patients unresponsive to at least three cycles of treatment were treated with daily-half doses of linezolid (600 mg once per day) plus at least four companion drugs.
Results: As of March 2006, eight patients, all HIV-negative, had been treated with linezolid for 3–18 months. Cultures became negative in all patients in an average of 82 days. Four patients developed peripheral neuropathy, two developed optic neuropathy and one developed anaemia. Although optic neuropathy resolved after cessation of linezolid therapy, peripheral neuropathy continued. One patient completed 18 months of linezolid therapy. Two patients, who have taken linezolid for 15–17 months, are still on treatment and remain in culture conversion. Three patients stopped linezolid after 7–9 months, two because of side effects and one for economic reasons, but remain on treatment with other second-line drugs with culture conversion. Two patients died from severe respiratory failure, but both previously had shown culture conversion.
Conclusions: Although daily-half doses of linezolid were effective in patients with intractable or extensive MDR-TB, this dosage regimen did not reduce long-term use-related side effects, such as peripheral and optic neuropathy.
Keywords: oxazolidinones , Mycobacterium tuberculosis , treatment failure , adverse effects
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. Vera-Cabrera, N. A. Espinoza-Gonzalez, O. Welsh, J. Ocampo-Candiani, and J. Castro-Garza Activity of novel oxazolidinones against Nocardia brasiliensis growing within THP-1 macrophages J. Antimicrob. Chemother., November 1, 2009; 64(5): 1013 - 1017. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-J. Koh and T. S. Shim Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis--authors' response J. Antimicrob. Chemother., November 1, 2009; 64(5): 1119 - 1120. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Jeon, O J. Kwon, N. Y. Lee, B.-J. Kim, Y.-H. Kook, S.-H. Lee, Y. K. Park, C. K. Kim, and W.-J. Koh Antibiotic Treatment of Mycobacterium abscessus Lung Disease: A Retrospective Analysis of 65 Patients Am. J. Respir. Crit. Care Med., November 1, 2009; 180(9): 896 - 902. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-J. Koh and T. S. Shim Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis--authors' response J. Antimicrob. Chemother., October 1, 2009; 64(4): 883 - 884. [Full Text] [PDF]
|
|
|
|
 |
|
 B. McGee, R. Dietze, D. J. Hadad, L. P. D. Molino, E. L. N. Maciel, W. H. Boom, M. Palaci, J. L. Johnson, and C. A. Peloquin Population Pharmacokinetics of Linezolid in Adults with Pulmonary Tuberculosis Antimicrob. Agents Chemother., September 1, 2009; 53(9): 3981 - 3984. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. N. Williams, S. J. Brickner, C. K. Stover, T. Zhu, A. Ogden, R. Tasneen, S. Tyagi, J. H. Grosset, and E. L. Nuermberger Addition of PNU-100480 to First-Line Drugs Shortens the Time Needed to Cure Murine Tuberculosis Am. J. Respir. Crit. Care Med., August 15, 2009; 180(4): 371 - 376. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. B. Migliori, B. Eker, M. D. Richardson, G. Sotgiu, J-P. Zellweger, A. Skrahina, J. Ortmann, E. Girardi, H. Hoffmann, G. Besozzi, et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis Eur. Respir. J., August 1, 2009; 34(2): 387 - 393. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-J. Koh, O. J. Kwon, H. Gwak, J. W. Chung, S.-N. Cho, W. S. Kim, and T. S. Shim Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis J. Antimicrob. Chemother., August 1, 2009; 64(2): 388 - 391. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. N. Williams, C. K. Stover, T. Zhu, R. Tasneen, S. Tyagi, J. H. Grosset, and E. Nuermberger Promising Antituberculosis Activity of the Oxazolidinone PNU-100480 Relative to That of Linezolid in a Murine Model Antimicrob. Agents Chemother., April 1, 2009; 53(4): 1314 - 1319. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. W. Yew and C. C. Leung Update in Tuberculosis 2008 Am. J. Respir. Crit. Care Med., March 1, 2009; 179(5): 337 - 343. [Full Text] [PDF]
|
|
|
|
 |
|
 W. W. Yew and C. C. Leung How Should We Treat "Difficult" Multidrug-Resistant Tuberculosis? Chest, February 1, 2009; 135(2): 587 - 588. [Full Text] [PDF]
|
|
|
|
 |
|
 E. S. Guy and A. Mallampalli Review: Managing TB in the 21st century: existing and novel drug therapies Therapeutic Advances in Respiratory Disease, December 1, 2008; 2(6): 401 - 408. [Abstract] [PDF]
|
|
|
|
|
|
R. Dietze, D. J. Hadad, B. McGee, L. P. D. Molino, E. L. N. Maciel, C. A. Peloquin, D. F. Johnson, S. M. Debanne, K. Eisenach, W. H. Boom, et al. Early and Extended Early Bactericidal Activity of Linezolid in Pulmonary Tuberculosis Am. J. Respir. Crit. Care Med., December 1, 2008; 178(11): 1180 - 1185. [Abstract] [Full Text] [PDF]
|
|